Jazz Pharmaceuticals to Acquire Chimerix for ~$935M
Shots:
- Jazz Pharmaceuticals to acquire Chimerix for ~$935M at a price of $8.55 per share in cash. Upon completion in Q2’25, Jazz will acquire remaining shares via second-step merger
- Acquisition will strengthen Jazz’s rare oncology presence through development & launch of Chimerix’s lead asset, dordaviprone, while adding durable revenue potential with patent protection through 2037 & possible extension
- Dordaviprone is under the US FDA priority review (PDUFA: Aug 18, 2025) with potential RPD PRV post approval, plus it is being evaluated in an ongoing P-III (ACTION) trial for naïve, non-recurrent H3 K27M-mutant glioma post-radiation, potentially expanding its use to 1L pts
Ref: Prnewswire | Image: Chimerix
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
